Motilal Oswal said Q4 FY26 earnings surpassed expectations, with aggregate profits rising 16% year-on-year against its 8% estimate. Strong ...

Corporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...

Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...

Indian equity markets are consolidating within a narrow range, with Nifty struggling to break 24,000 and Bank Nifty showing relative streng...

Indian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...

Global markets are under pressure due to rising bond yields and geopolitical tensions. Higher crude oil prices are a key concern, potential...

Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...

The Delhi High Court has ruled against Reddy Pharmaceuticals. The court upheld a decision to remove 'Reddy' from the company's name. Reddy ...

Indian fund managers focused on defensive stocks in April. Pharmaceuticals saw increased investment due to opportunities like the semagluti...

Dr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared w...

Markets experienced a sharp risk-off session on Monday, with indices declining amid broad selling. Investors are advised to avoid aggressiv...

Indian stock markets are set for a busy week. Key events like Q4 earnings announcements for many companies will influence trading. Foreign ...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...

Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

Market expert Sudip Bandyopadhyay warns Indian markets face significant risks. High oil prices and a potential monsoon deficit are major co...

Sun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...